Evidence map›Paper›PMID 19879194›Full record

ArticleThe Lancet. Neurology2009

Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score.

Philip L De Jager, Lori B Chibnik, Jing Cui, Joachim Reischl, Stephan Lehr, K Claire Simon, Cristin Aubin, David Bauer, Jürgen F Heubach, Rupert Sandbrink and 12 more

Registry-linked trialAbstract read
In one paragraph

Article in The Lancet. Neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00185211 (Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study), which is not on this map. Cited by 119 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00185211 phase3completednot on this map

Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study (no. 92012/304747) to Obtain Long-term Follow-up Data of Patients With Clinically Definite Multiple Sclerosis (MS) and Patients With a First Demyelinating Event Suggestive of MS Treated With 8 MIU (250 µg) Interferon Beta-1b (Betaferon® / Betaseron®) Given Subcutaneously Every Other Day for at Least 36 Months.

TypeinterventionalSponsorBayerRan2002 to 2008Enrolled468ConditionsMultiple SclerosisArmsInterferon beta-1b (Betaseron, BAY86-5046)
3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Epstein-Barr virus flare: A multiple sclerosis attack.Surgical neurology international · 2024
    Review
  17. Article
  18. Risk HLA Variants Affect the T-Cell Repertoire in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2023
    Article
  19. Article
  20. Review

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Philip L De JagerProgram in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA. pdejager@rics.bwh.harvard.edu
Lori B Chibnik
Jing Cui
Joachim Reischl
Stephan Lehr
K Claire Simon
Cristin Aubin
David Bauer
Jürgen F Heubach
Rupert Sandbrink
Michaela Tyblova
Petra Lelkova
Steering committee of the BENEFIT study
Steering committee of the BEYOND study
Steering committee of the LTF study
Steering committee of the CCR1 study
Eva Havrdova
Christoph Pohl
Dana Horakova
Alberto Ascherio
David A Hafler
Elizabeth W Karlson

Funding

Interdisciplinary Training in Genes and the EnvironmentT32ES016645 · NIEHS · HARVARD SCHOOL OF PUBLIC HEALTH · PI LEE, CHIH-HAO · 2008 to 2018
$4.0M
Medical Research Council G0000934NIEHS NIH HHS T32 ES016645NIEHS NIH HHS T32 ES16645-01Wellcome Trust
6 · The paper itself

Abstract

backgroundPrediction of susceptibility to multiple sclerosis (MS) might have important clinical applications, either as part of a diagnostic algorithm or as a means to identify high-risk individuals for prospective studies. We investigated the usefulness of an aggregate measure of risk of MS that is based on genetic susceptibility loci. We also assessed the added effect of environmental risk factors that are associated with susceptibility for MS.

methodsWe created a weighted genetic risk score (wGRS) that includes 16 MS susceptibility loci. We tested our model with data from 2215 individuals with MS and 2189 controls (derivation samples), a validation set of 1340 individuals with MS and 1109 controls taken from several MS therapeutic trials (TT cohort), and a second validation set of 143 individuals with MS and 281 controls from the US Nurses' Health Studies I and II (NHS/NHS II), for whom we also have data on smoking and immune response to Epstein-Barr virus (EBV).

findingsIndividuals with a wGRS that was more than 1.25 SD from the mean had a significantly higher odds of MS in all datasets. In the derivation sample, the mean (SD) wGRS was 3.5 (0.7) for individuals with MS and 3.0 (0.6) for controls (p<0.0001); in the TT validation sample, the mean wGRS was 3.4 (0.7) for individuals with MS versus 3.1 (0.7) for controls (p<0.0001); and in the NHS/NHS II dataset, the mean wGRS was 3.4 (0.8) for individuals with MS versus 3.0 (0.7) for controls (p<0.0001). In the derivation cohort, the area under the receiver operating characteristic curve (C statistic; a measure of the ability of a model to discriminate between individuals with MS and controls) for the genetic-only model was 0.70 and for the genetics plus sex model was 0.74 (p<0.0001). In the TT and NHS cohorts, the C statistics for the genetic-only model were both 0.64; adding sex to the TT model increased the C statistic to 0.72 (p<0.0001), whereas adding smoking and immune response to EBV to the NHS model increased the C statistic to 0.68 (p=0.02). However, the wGRS does not seem to be correlated with the conversion of clinically isolated syndrome to MS.

interpretationThe inclusion of 16 susceptibility alleles into a wGRS can modestly predict MS risk, shows consistent discriminatory ability in independent samples, and is enhanced by the inclusion of non-genetic risk factors into the algorithm. Future iterations of the wGRS might therefore make a contribution to algorithms that can predict a diagnosis of MS in a clinical or research setting.

Indexed as

AlgorithmsAdolescentAdultAgedAllelesChildChild, PreschoolCohort StudiesEnvironmentFemaleGenotypeHumansMaleMiddle AgedMultiple SclerosisOdds Ratio

Identifiers

PMID19879194
PMCPMC3099419

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.